Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SEM
SEM logo

SEM Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Select Medical Holdings Corp (SEM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
--
1 Day change
-0.12%
52 Week Range
16.990
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Select Medical Holdings Corp (SEM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is being acquired for $16.50 per share in cash, effectively capping its upside potential. Additionally, there are no significant trading signals or positive catalysts to suggest a compelling entry point.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 36.171, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 16.604, with resistance at 16.676 and support at 16.531. However, the pre-market price drop of -2.05% suggests short-term weakness.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
5

Positive Catalysts

  • NULL. The stock is being acquired at a fixed price of $16.50 per share, limiting any upside potential.

Neutral/Negative Catalysts

  • The merger deal caps the stock price at $16.50, eliminating growth potential. Legal investigations into the fairness of the merger may create uncertainty, but they are unlikely to impact the agreed-upon price.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Mizuho downgraded the stock to Neutral from Outperform with a price target of $16.50, aligning with the acquisition price. Analysts consider the $16.50 cash offer fair.

Wall Street analysts forecast SEM stock price to rise
4 Analyst Rating
Wall Street analysts forecast SEM stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.510
sliders
Low
17
Averages
18.75
High
21
Current: 16.510
sliders
Low
17
Averages
18.75
High
21
Mizuho
Ann Hynes
Outperform -> Neutral
downgrade
$17
AI Analysis
2026-05-12
Reason
Mizuho
Ann Hynes
Price Target
$17
AI Analysis
2026-05-12
downgrade
Outperform -> Neutral
Reason
Mizuho analyst Ann Hynes downgraded Select Medical to Neutral from Outperform with a price target of $16.50, down from $17. The company is being taken private with the deal expected to close in mid-2026, pending shareholder approval, the analyst tells investors in a research note. Mizuho views the $16.50 in cash per share price as fair.
RBC Capital
Outperform
maintain
$20 -> $19
2026-02-23
Reason
RBC Capital
Price Target
$20 -> $19
2026-02-23
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Select Medical to $19 from $20 and keeps an Outperform rating on the shares. The stock declined about 7% on Friday after the company reported a Q4 adjusted EBITDA miss and softer-than-expected 2026 guidance, though the firm is encouraged that management does not expect a material headwind related to the high-cost outlier threshold within its CIRH segment in 2026, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SEM
Unlock Now

People Also Watch